Very successful capital increase of NFL Biosciences with more than 3 million euros raised
• Strong success of placement with professional investors with a diversified base of French and international investors for an amount of €2.45 million.
• Exceptional participation of private individuals via the PrimaryBid platform with an offer nearly 3 times oversubscribed and nearly 1,000 orders received for an amount of €1.6 million, allocated at €0.6 million.
• Subscription price set at €2.23 per new share, mid-range.
• A secure cash horizon over more than 12 months allowing NFL Biosciences to reach in 2023 the key stages of validation of the two ongoing studies on NFL-101 as a smoking cessation aid.
• Settlement delivery of new shares on February 2, 2023.
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions (the “Company”), announces today the strong success of its fundraising for a total amount of 3 €059,910.11 by way of capital increases with cancellation of shareholders’ preferential subscription rights in favor of professional investors up to €2.5 million on the one hand, and individual investors on the other via the PrimaryBid platform for €0.6 million (the “Transaction”).